MAP2K7 and lung carcinoma: MAPK signaling has been known to be essential for KRAS-induced lung tumorigenesis [16], and pharmacological inhibition of this pathway (e.g., MEK inhibitor) has been attempted to treat KRAS-driven lung cancers.